Education
About Us
Working with TipRanks
Follow Us
Merus NV (MRUS)
NASDAQ:MRUS
MRUS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$37.77 - $61.61
Previous CloseN/A
Volume56.75K
Average Volume (3M)611.90K
Market Cap
$3.29B
Enterprise Value$2.79B
Total Cash (Recent Filing)$293.29M
Total Debt (Recent Filing)$9.91M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
May 13, 2025EPS Estimate
-1.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.31
Shares Outstanding69,090,470
10 Day Avg. Volume756,976
30 Day Avg. Volume611,903
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)89.39
Price to Cash Flow (P/CF)-12.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.85
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit77.18
Enterprise Value/Ebitda-9.61
Forecast
1Y Price Target
$87.83Price Target Upside78.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
---
Merus News
PremiumCompany Announcements
Merus N.V. Reports 2024 Earnings and Clinical Progress
---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentPetosemtamab continues to show impressive efficacy and safety in HNSCC indications, now with breakthrough therapy and fast-track designations in both 1L and 2L+ settings.
Financial HealthThe company reported cash and cash equivalents of $724mn, which they estimate will provide a cash runway into 2028.
Regulatory ApprovalsThe FDA's granting of Breakthrough Therapy Designation for peto reinforces its differentiated profile and continues to give investors confidence.
Bears Say
---
Ownership Overview
0.46% Insiders
21.06% Mutual Funds
4.70% Other Institutional Investors
72.03% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MRUS FAQ
What was Merus NV’s price range in the past 12 months?
Merus NV lowest stock price was $37.77 and its highest was $61.61 in the past 12 months.
What is Merus NV’s market cap?
Merus NV’s market cap is $3.29B.
When is Merus NV’s upcoming earnings report date?
Merus NV’s upcoming earnings report date is May 13, 2025 which is in 61 days.
How were Merus NV’s earnings last quarter?
Merus NV released its earnings results on Feb 27, 2025. The company reported -$0.45 earnings per share for the quarter, beating the consensus estimate of -$0.89 by $0.44.
Is Merus NV overvalued?
According to Wall Street analysts Merus NV’s price is currently Undervalued.
Does Merus NV pay dividends?
Merus NV does not currently pay dividends.
What is Merus NV’s EPS estimate?
Merus NV’s EPS estimate is -1.06.
How many shares outstanding does Merus NV have?
Merus NV has 69,090,470 shares outstanding.
What happened to Merus NV’s price movement after its last earnings report?
Merus NV reported an EPS of -$0.45 in its last earnings report, beating expectations of -$0.89. Following the earnings report the stock price went up 1.882%.
Which hedge fund is a major shareholder of Merus NV?
Currently, no hedge funds are holding shares in MRUS
---
Merus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$87.83 (78.66% Upside)
$87.83 (78.66% Upside)
Blogger Sentiment
Bullish
MRUS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 352.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 5.4%
Last 30 Days ▼ 5.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.29%
12-Months-Change
Fundamentals
Return on Equity
-42.88%
Trailing 12-Months
Asset Growth
71.24%
Trailing 12-Months
Company Description
Merus NV
Merus NV is a clinical-stage immune-oncology company, which engages in the discovery and development of bi-specific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.
---
MRUS Stock 12 Month Forecast
Average Price Target
$87.83
▲(78.66% Upside)
Technical Analysis
Best Analysts Covering MRUS
1 Year
1 Year Success Rate
7/11 ratings generated profit
1 Year Average Return
+19.35%
reiterated a buy rating 6 days ago
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +19.35% per trade.
---